Hikma Pharmaceuticals PLC (HIK.L)
LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:38PM BST
| Previous Close | 1,960.00 |
| Open | 1,994.00 |
| Bid | 1,750.00 x 0 |
| Ask | 2,222.00 x 0 |
| Day's Range | 1,956.00 - 2,000.00 |
| 52 Week Range | 1,711.00 - 2,222.00 |
| Volume | |
| Avg. Volume | 624,967 |
| Market Cap | 4.34B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 28.76 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.57 (2.93%) |
| Ex-Dividend Date | Mar 21, 2024 |
| 1y Target Est | N/A |
- Simply Wall St.
With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...
- Simply Wall St.
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
- Reuters
Merck's Bridion faces generic threat from drugmaker Hikma
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.
© 2024 Yahoo. All rights reserved.